Biogen/Sobi's Eloctate meets all endpoints in Kids trial

Save

Eloctate, a long-acting Factor VIII fusion protein, was well tolerated in patients enrolled in the Phase III Kids A-LONG study. The primary endpoint of the study was to evaluate the frequency of inhibitor (neutralising antibody) development and none were…